AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11085844 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0
Study 11085844 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss interventions
Number of subjects: 0
Study 11085844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening methods
Number of subjects: 0
Study 11085844 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic violence interventions
Number of subjects: 0
Study 11085844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual dysfunction treatments
Number of subjects: 0
Study 8694302 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HES (mean molecular weight 200,000 daltons)
Number of subjects: 60
Study 8694302 — intervention group
Group type: COMPARATOR
Intervention: Human albumin 20% (HA)
Number of subjects: 60
Study 1550062 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 47
Study 1550062 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 47
Study 1550062 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 47
Study 4016827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1,000 mg once daily
Number of subjects: 200
Study 4016827 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg TID
Number of subjects: 200
Study 4016827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 200
Study 4016827 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 200
Study 31469026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (IngMeb)
Number of subjects: 502
Study 31469026 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (DS)
Number of subjects: 502
Study 30886933 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week physical activity and nutrition program
Number of subjects: 576
Study 30886933 — intervention group
Group type: COMPARATOR
Intervention: 4-session health and wellness workshop
Number of subjects: 576
Study 28452086 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 117
Study 28452086 — intervention group
Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 117
Study 28452086 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Atosiban
Number of subjects: 117
Study 26310909 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided CESI
Number of subjects: 186
Study 26310909 — intervention group
Group type: EXPERIMENTAL
Intervention: CLO fluoroscopy-guided CESI
Number of subjects: 186
Study 26310909 — intervention group
Group type: COMPARATOR
Intervention: APL fluoroscopy-guided CESI
Number of subjects: 186
Study 24743675 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with double-sided polypropylene mesh (29 patients)
Number of subjects: 60
Study 24743675 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication without mesh (31 patients)
Number of subjects: 60
Study 22282429 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT)
Number of subjects: 90
Study 22282429 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 90
Study 22282429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IPT and CBT
Number of subjects: 90
Study 20167476 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR gene amplification assessment using fluorescent in situ hybridisation
Number of subjects: 315
Study 18716314 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic enoxaparin (40 mg, single-dose subcutaneous administration)
Number of subjects: 20
Study 16273477 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic ICA stenosis ≥70% (GI)
Number of subjects: 109
Study 16273477 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic ICA stenosis (GII)
Number of subjects: 109
Study 16273477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study 16273477 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic ICA stenosis (GI)
Number of subjects: 109
Study 16273477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GI and GII)
Number of subjects: 109
Study 12234503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Number of subjects: 1218
Study 12234503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study 10550150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 plus cisplatin 100 mg/m² on day 2, every 28 days
Number of subjects: 307
Study 10550150 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin 6 mg/m², ifosfamide 3,000 mg/m², and mesna on day 1 plus cisplatin 100 mg/m² on day 2, every 28 days
Number of subjects: 307
Study 10550150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin (GC)
Number of subjects: 307
Study 10550150 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin, ifosfamide, and cisplatin (MIC)
Number of subjects: 307
Study 7770260 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day of elemental calcium
Number of subjects: 75
Study 7770260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 7770260 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 75
Study 7770260 — intervention group
Group type: COMPARATOR
Intervention: Calcium and Placebo
Number of subjects: 75
Study 1703780 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 0
Study 378732 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (1 mg and 2 mg)
Number of subjects: 200
Study 378732 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (40 mg and 80 mg)
Number of subjects: 200
Study 378732 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 200
Study 378732 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 200
Study 31912371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibration device (AcceleDent Aura)
Number of subjects: 21
Study 30556911 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib ointment applied twice daily for 4 weeks
Number of subjects: 0
Study 30556911 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 28092795 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training (EX, n=210)
Number of subjects: 419
Study 28092795 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (NON-EX, n=209)
Number of subjects: 419
Study 26605849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with subretinal delivery of a recombinant adeno‐associated viral vector carrying RPE65
Number of subjects: 8
Study 23218844 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted form of individual short‐term psychodynamic psychotherapy (ASTPP) - 25 sessions, 1 session/week
Number of subjects: 46
Study 23218844 — intervention group
Group type: COMPARATOR
Intervention: Primary care management (TAU) - 4 consultations/6 months
Number of subjects: 46
Study 23218844 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTPP
Number of subjects: 46
Study 23218844 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 46
Study 21615309 — intervention group
Group type: EXPERIMENTAL
Intervention: scTox-Tr group (n = 19) - patients who adhered to the exercise intervention
Number of subjects: 36
Study 21615309 — intervention group
Group type: COMPARATOR
Intervention: scTox-Sed group (n = 17) - patients who did not adhere to the exercise intervention
Number of subjects: 36
Study 21615309 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - 48 subjects
Number of subjects: 36
Study 19547808 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (n=115, 75-600 mg)
Number of subjects: 325
Study 19547808 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (n=105, dose range 2-15 mg)
Number of subjects: 325
Study 19547808 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (n=105, 100-400 mg)
Number of subjects: 325
Study 16679276 — intervention group
Group type: EXPERIMENTAL
Intervention: FAIR (Flow‐sensitive Alternating Inversion Recovery) magnetic resonance imaging technique
Number of subjects: 26
Study 14560228 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant Beriplast P (FSBP)
Number of subjects: 201
Study 14560228 — intervention group
Group type: COMPARATOR
Intervention: Thrombin-soaked gelatin sponge (TSG)
Number of subjects: 201
Study 10352065 — intervention group
Group type: EXPERIMENTAL
Intervention: Witness Project (culturally competent cancer education program)
Number of subjects: 410
Study 10352065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 410
Study 8879890 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg PO QD, titrated to 50 mg losartan/12.5 mg HCTZ PO QD after 4 weeks, then to 50 mg losartan/25 mg HCTZ PO QD after 8 weeks)
Number of subjects: 190
Study 8879890 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg PO QD, titrated to 10 mg PO QD after 4 weeks, then to 10 mg plus 25 mg HCTZ PO QD after 8 weeks)
Number of subjects: 190
Study 1999863 — intervention group
Group type: EXPERIMENTAL
Intervention: Skewflap
Number of subjects: 191
Study 1999863 — intervention group
Group type: COMPARATOR
Intervention: Long posterior flap
Number of subjects: 191
Study 6465669 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled vasoactive intestinal peptide (VIP) 100 micrograms
Number of subjects: 6
Study 6465669 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 6
Study 6465669 — intervention group
Group type: COMPARATOR
Intervention: Control solution (1% human serum albumin in 2 ml 0.9% saline)
Number of subjects: 6
Study 30779971 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) with bioDensity™
Number of subjects: 300
Study 29433457 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing a mix of dairy fat and plant oils (D)
Number of subjects: 70
Study 29433457 — intervention group
Group type: COMPARATOR
Intervention: Formula containing plant oils (P)
Number of subjects: 70
Study 29433457 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing plant oils supplemented with ARA and DHA (PDHA)
Number of subjects: 70
Study 29433457 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants (BF)
Number of subjects: 70
Study 29433457 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 70
Study 26875905 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave therapy (SW group)
Number of subjects: 52
Study 26875905 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug therapy)
Number of subjects: 52
Study 24824095 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 56
Study 24824095 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (nonweight bearing and early range of motion exercise)
Number of subjects: 56
Study 23190521 — intervention group
Group type: EXPERIMENTAL
Intervention: High flux dialyzers
Number of subjects: 312
Study 23190521 — intervention group
Group type: COMPARATOR
Intervention: Low flux dialyzers
Number of subjects: 312
Study 20716300 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment addressing anxiety symptoms
Number of subjects: 526
Study 17055165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency
Number of subjects: 23
Study 17055165 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 23
Study 16294506 — intervention group
Group type: EXPERIMENTAL
Intervention: New nevirapine tablet formulation (test, T)
Number of subjects: 24
Study 16294506 — intervention group
Group type: COMPARATOR
Intervention: Reference nevirapine tablet formulation (R)
Number of subjects: 24
Study 11923816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (bemiparin sodium 3500 IU/daily subcutaneously)
Number of subjects: 100
Study 9917487 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula A (Similac With Iron Powder)
Number of subjects: 169
Study 9917487 — intervention group
Group type: COMPARATOR
Intervention: Formula B (Enfamil With Iron Powder)
Number of subjects: 169
Study 9917487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 169
Study 9917487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from breast milk to formula A
Number of subjects: 169
Study 7577777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine followed by a continuous infusion of 7 mL/h 0.25% bupivacaine
Number of subjects: 30
Study 7577777 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 30
Study 7577777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine
Number of subjects: 30
Study 7577777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 2122869 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg/day after impregnation)
Number of subjects: 43
Study 2122869 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 43
Study 2122869 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase (2 weeks) followed by 6 weeks of active treatment
Number of subjects: 43
Study 354922 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 45
Study 354922 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 45
Study 31791239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 1 μg·kg‐1
Number of subjects: 40
Study 31791239 — intervention group
Group type: COMPARATOR
Intervention: Normal saline at 0.01 ml·kg‐1
Number of subjects: 40
Study 28932090 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (400 mg) HL tablet
Number of subjects: 74
Study 28932090 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (133.4 mg) HL tablet
Number of subjects: 74
Study 28932090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 26116614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined functional anaerobic and strength training (12-week programme, 3 sessions per week, 75 minutes each session)
Number of subjects: 40
Study 24120711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 1200
Study 24120711 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 1200
Study 24120711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 21471845 — intervention group
Group type: EXPERIMENTAL
Intervention: Artcereb (artificial cerebrospinal fluid)
Number of subjects: 20
Study 21471845 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 20
Study 19217598 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F vacuum drain plus COSEAL
Number of subjects: 77
Study 19217598 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F vacuum drain plus BioGlue
Number of subjects: 77
Study 19217598 — intervention group
Group type: COMPARATOR
Intervention: 18F vacuum drain
Number of subjects: 77
Study 17596727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 32
Study 15285274 — intervention group
Group type: COMPARATOR
Intervention: Gingko biloba (GB)
Number of subjects: 60
Study 15285274 — intervention group
Group type: COMPARATOR
Intervention: Combination of Codonopsis pilosula (CPG) and Gingko biloba (GB)
Number of subjects: 60
Study 15285274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11583941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus at 2 mg/d
Number of subjects: 719
Study 11583941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus at 5 mg/d
Number of subjects: 719
Study 11583941 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 719
Study 11583941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (both doses)
Number of subjects: 719
Study 11583941 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Sirolimus and Azathioprine)
Number of subjects: 719
Study 11583941 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 719
Study 9250437 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 14
Study 9250437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 14
Study 7936292 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded levels of dysphagia therapist control of diet consistency and reinforcement of compensatory swallowing techniques
Number of subjects: 115
Study 7936292 — intervention group
Group type: COMPARATOR
Intervention: Limited patient and family instruction regarding diet modification and compensatory swallowing techniques
Number of subjects: 115
Study 2643672 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine chewing gum
Number of subjects: 223
Study 2643672 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention alone (no gum)
Number of subjects: 223
Study 786045 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (20 mg) in fast condition
Number of subjects: 6
Study 786045 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (20 mg) in slow condition
Number of subjects: 6
Study 786045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 786045 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (intoxicating doses)
Number of subjects: 6
Study 30717700 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshops (two four-hour sessions) and homework assignments on advance care planning and shared decision-making.
Number of subjects: 311
Study 30717700 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshops and supporting materials for staff.
Number of subjects: 311
Study 28479221 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions based on the Common-Sense Model of Self-Regulation (CSM) to change parental illness perception.
Number of subjects: 0
Study 28479221 — intervention group
Group type: COMPARATOR
Intervention: Caregivers who believed baby teeth do matter.
Number of subjects: 0
Study 25746966 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 1264
Study 25746966 — intervention group
Group type: COMPARATOR
Intervention: Inhaled ipratropium bromide
Number of subjects: 1264
Study 25746966 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (budesonide)
Number of subjects: 1264
Study 24519693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone
Number of subjects: 0
Study 24519693 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study 21627766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 1,200 mg (624 mg-equivalents gabapentin), twice daily for 14 days
Number of subjects: 101
Study 21627766 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 14 days
Number of subjects: 101
Study 21627766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn)
Number of subjects: 101
Study 21627766 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin capsules
Number of subjects: 101
Study 19656101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 123
Study 22157410 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 611
Study 22157410 — intervention group
Group type: COMPARATOR
Intervention: Non-CABG (percutaneous coronary intervention plus medical treatment)
Number of subjects: 611
Study 16507375 — intervention group
Group type: EXPERIMENTAL
Intervention: CSDVC (clindamycin phosphate 2% single-dose vaginal cream)
Number of subjects: 0
Study 16507375 — intervention group
Group type: COMPARATOR
Intervention: CVC (7-day regimen of clindamycin phosphate 2% vaginal cream)
Number of subjects: 0
Study 16507375 — intervention group
Group type: EXPERIMENTAL
Intervention: CSDVC
Number of subjects: 0
Study 16507375 — intervention group
Group type: COMPARATOR
Intervention: CVC
Number of subjects: 0
Study 12869610 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg tablet)
Number of subjects: 11
Study 12869610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10219129 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark, IMZ or Frialit‐2 endosseous implants with autogenous bone grafts
Number of subjects: 50
Study 10219129 — intervention group
Group type: COMPARATOR
Intervention: Oral implants in periodontally healthy patients
Number of subjects: 50
Study 10219129 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ, Brånemark and Frialit‐2 abutments
Number of subjects: 50
Study 7597209 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium-192 boost (20 Gy)
Number of subjects: 255
Study 7597209 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-60 boost (20 Gy)
Number of subjects: 255
Study 7597209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study 2362111 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation bag controller (RC)
Number of subjects: 25
Study 2362111 — intervention group
Group type: COMPARATOR
Intervention: Manual resuscitation bags (MRB)
Number of subjects: 25
Study 2362111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (RC and MRB)
Number of subjects: 25
Study 469022 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate
Number of subjects: 20
Study 469022 — intervention group
Group type: COMPARATOR
Intervention: Quinidine gluconate
Number of subjects: 20
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1342
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1342
Study 11311100 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose levels
Number of subjects: 1342
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1342
Study 11311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated IFG
Number of subjects: 1342